Book a Meeting

Ribosomal Marker Antibody Development Services

Background Our Service Highlights FAQs Published Data Resource


Overview of Ribosomal Marker Antibody Development

Ribosomal proteins were originally viewed as complements for rRNA in ribosomes but are now emerging as mediators of a variety of checkpoint pathways that link ribosome biogenesis to the cell cycle and other cellular functions. The TOR pathway is a central regulator of ribosome biogenesis at multiple levels. TOR links nutrient availability to cell growth and ribosome synthesis. TOR is activated in multiple human cancers where it drives ribosome biogenesis, which is necessary for the unlimited growth of cancer cells. Another major regulator of ribosome biogenesis in cancer cells is the transcription factor heat shock factor 1 (HSF1) which coordinates the transcription of proteins and RNAs required for translation with many other anabolic processes. In addition, despite the clear link between the production of ribosomes and cancer, some ribosomal proteins can trigger anti-cancer responses. The characterization of the structural motifs that mediate all nonribosomal functions of ribosomal proteins will offer insights to explain the evolution of anticancer responses and new targets to develop new anticancer drugs. In this context, ribosomal marker antibody development becomes an attractive and meaningful project.

Ribosome-free ribosomal proteins (RPs) link ribosome biogenesis to tumor suppressor pathways.Fig.1 Ribosome-free ribosomal proteins (RPs) link ribosome biogenesis to tumor suppressor pathways. (Lessard, 2019)

Example-Anti-ribosomal P (anti-P) antibody - A Striking ribosomal antibody

Ribosomal Marker Antibody Development Services

Anti-ribosomal P (anti-P) antibody in Systemic Lupus Erythematosus (SLE) received considerable attention in recent studies. This antibody recognizes three specific ribosomal phosphoproteins known as P0 (38 kDa), P1 (19 kDa), and P2 (17 kDa). A homologous 22-amino acid C-terminal (C-22) sequence shared by the three proteins is used as the dominant immunoreactive domain to detect anti-P antibodies in SLE. The prevalence of serum anti-P antibodies varies from 15% to 40% in SLE. The anti-P antibody has been suggested to be a specific serological marker for SLE by a few studies regarding antibody specificity and sensitivity. Anti-P antibody was specifically detected in patients with SLE, but not in patients with other rheumatic disorders, patients with chemotherapy-induced cell damage, or healthy controls. A few studies showed that the anti-P antibody was strongly correlated with SLE disease activity, and was observed to be associated with SLE-related neuropsychiatric, renal, and hepatic disorders.

Our Service

As ribosomes have been found to play important roles in many diseases, many scientists have focused their attention on the ribosome. In this context, ribosomal marker antibody development has become a meaningful project. As an experienced antibody development expert, Creative Biolabs has also been focusing on ribosomes over years. Accumulated from years of practice, our platform has been optimized step by step with up-to-date technologies, advanced equipment, and experienced scientists. With all of these foundations, we are confident in providing customer-satisfied services to global clients.


  • Years of Expertise

With years of concentrated practice and utilization of advanced technologies and systems, our well-experienced scientists guarantee high-quality ribosomal marker antibody development services.

  • Advanced Technologies

Our years of expertise in antibody development, combined with our state-of-the-art technologies, advanced equipment, and dedicated team of scientists, allow us to provide top-notch services in the field of ribosomal marker antibody development.

  • Global Clientele and High Satisfaction Rate

Our commitment to delivering excellent services rooted in refined practice and deep knowledge has gained us a diverse and global clientele with high satisfaction rates.


Q1: What is Creative Biolabs' role in ribosomal marker antibody development?

A: Creative Biolabs is an experienced antibody development expert that has focused on ribosomes for many years. The platform has been refined over time with the latest technologies and experienced scientists. Creative Biolabs offers global clients customer-satisfied services in ribosomal marker antibody development.

Q2: What specialized skills and technologies does Creative Biolabs utilize for their ribosome research operations?

A: Committed to excellence, Creative Biolabs boasts a comprehensive experimental platform dedicated solely to ribosome purification and analysis. We employ a professional team, well-versed in both theoretical knowledge and practical applications of ribosome isolation and analysis. We pride ourselves on offering a comprehensive array of high quality, cost-effective, and streamlined ribosome research services.

Q3: Can you provide guidance on how I can delve further into the range of services offered by Creative Biolabs in relation to ribosomes?

A: We encourage you to connect with our team of specialists for more detailed information. For those with specific requirements, there is an option to request a personalized quote. If you prefer a more general inquiry, simply reach out to us and we will design a solution tailored to your unique needs.

Published Data

Antibodies to ribosomal P proteins in lupus nephritis: A surrogate marker for a better renal survival?


Authors: Patrícia Andrade de Macedo, Eduardo Ferreira Borba, et al.

To define if antibodies to ribosomal P proteins disclose a better lupus nephritis long-term survival.

Sixty consecutive SLE patients with biopsy-proven nephritis (2004 ISN/RPS) were evaluated for renal survival parameters. Inclusion criteria were at least one serum sample at: renal flares, biopsy, and last follow-up until 2008. Anti-P was detected by ELISA/immunoblot and anti-dsDNA by indirect immunofluorescence/ELISA.

Eleven patients (18%) with anti-P+ (without anti-dsDNA) during renal flare were compared to 49 (82%) persistently negative for anti-P throughout the study. At the final follow-up post-biopsy (6.3 ± 2.5 vs. 6.8 ± 2.4 years, p = 0.36), the comparison of anti-P+/anti-dsDNA− with anti-P− group revealed a trend to lower mean creatinine levels (0.9 ± 0.3 vs. 2.3 ± 2.1 mg/dl, p = 0.07), lower frequency of dialysis (0% vs. 35%, p = 0.025), and higher frequency of normal renal function (91% vs. 53%, p = 0.037). The overall renal survival was significantly higher in anti-P+/anti-dsDNA− compared to anti-P− (11.0 ± 4.5 vs. 9.2 ± 4.5 years, p = 0.033), anti-dsDNA+/anti-P− (vs. 8.7 ± 4.7 years, p = 0.017), and anti-P−/anti-dsDNA− (vs. 9.8 ± 4.3 years, p = 0.09) groups.

Our data supports the notion that anti-P antibody in the absence of anti-dsDNA during nephritis flares is a valuable marker to predict a better long-term renal outcome in lupus patients.

Isolated anti-P has a better nephritis long-term survival than isolated anti-dsDNA or absence of both antibodies. (de Macedo, Patrícia Andrade, et al.; 2011)Isolated anti-P has a better nephritis long-term survival than isolated anti-dsDNA or absence of both antibodies. (de Macedo, Patrícia Andrade, et al.; 2011)


If you are interested in our ribosomal marker antibody development services or you have any other inquiries about our services, please feel free to contact us for more information.


  1. Lessard, F.; et al. Ribosomal Proteins Control Tumor Suppressor Pathways in Response to Nucleolar Stress. Bioessays. 2019, 41(3): e1800183.
For Research Use Only. We do not provide direct services or products for patients.
Online Inquiry
For Research Use Only. We do not provide direct services or products for patients.
Contact Us